Research programme: small molecule therapeutics - Vertex Pharmaceuticals
Latest Information Update: 20 Feb 2023
At a glance
- Originator Vertex Pharmaceuticals
- Class Antianaemics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Beta-thalassaemia; Sickle cell anaemia
Most Recent Events
- 30 Jan 2023 Early research in Beta-thalassaemia in USA (PO) (Vertex Pharmaceuticals pipeline, January 2023)
- 30 Jan 2023 Early research in Sickle cell anaemia in USA (PO) (Vertex Pharmaceuticals pipeline, January 2023)